Exclusive Summary

• The original patent for Tiopronin has fully expired with zero IP risk, making it an ideal mature generic for rapid market entry and overseas distribution.
• Targets a massive global demographic of hundreds of millions of patients with liver diseases (viral/fatty) and oncology patients undergoing chemo/radiotherapy, generating rigid hospital demand for hepatoprotection.
• Backed by China's integrated API-formulation manufacturing, the 0.1g lyophilized powder formulation offers a crushing cost advantage, ensuring absolute pricing power in local hospital tenders and high margins for distributors.